CN1307973C - Orally disintegrating tablet for dredging vascular thrombus and its preparation process - Google Patents
Orally disintegrating tablet for dredging vascular thrombus and its preparation process Download PDFInfo
- Publication number
- CN1307973C CN1307973C CNB2004100498494A CN200410049849A CN1307973C CN 1307973 C CN1307973 C CN 1307973C CN B2004100498494 A CNB2004100498494 A CN B2004100498494A CN 200410049849 A CN200410049849 A CN 200410049849A CN 1307973 C CN1307973 C CN 1307973C
- Authority
- CN
- China
- Prior art keywords
- oral cavity
- cavity disintegration
- disintegration tablet
- erythritol
- disintegrating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 208000007536 Thrombosis Diseases 0.000 title abstract description 5
- 230000002792 vascular Effects 0.000 title abstract 2
- 239000006191 orally-disintegrating tablet Substances 0.000 title description 2
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 50
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 37
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 37
- 239000004386 Erythritol Substances 0.000 claims abstract description 33
- 235000019414 erythritol Nutrition 0.000 claims abstract description 33
- 229940009714 erythritol Drugs 0.000 claims abstract description 33
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 24
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 24
- 229920002101 Chitin Polymers 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 210000000214 mouth Anatomy 0.000 claims description 66
- 239000009277 Panax notoginseng extract Substances 0.000 claims description 42
- 239000011734 sodium Substances 0.000 claims description 19
- 229910052708 sodium Inorganic materials 0.000 claims description 18
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 16
- 125000002057 carboxymethyl group Chemical class [H]OC(=O)C([H])([H])[*] 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 238000012856 packing Methods 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000013081 microcrystal Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 229940013618 stevioside Drugs 0.000 claims description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019202 steviosides Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 14
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000007924 injection Substances 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 65
- 241001465754 Metazoa Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- -1 polyethylene Polymers 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000019605 sweet taste sensations Nutrition 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000009748 deglutition Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Abstract
The present invention discloses an oral disintegrating tablet for dredging vascular thrombus and a preparation method thereof, wherein the oral disintegrating tablet is prepared from panax notoginseng saponin extracted from the main roots of notoginseng, and pharmaceutical adjuvant. The present invention also discloses a composite disintegrating agent for the oral disintegrating tablet, which is prepared from 30 wt% to 70 wt% of erythritol and chitin or a current frequently-used disintegrating agent. Experiments show that compared with the existing injection preparation, the oral disintegrating tablet prepared by the preparation method has the identical pharmacological action and has the advantages of convenient use and easy carry so as to be merrily accepted by patients.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of XUESHUANTONG oral cavity disintegration tablet and preparation method thereof.
Technical background
Oral cavity disintegration tablet is a kind of new pharmaceutical preparation, and it can absorb through hypoglossis mucous membrane, directly enters blood, has avoided first pass effect effectively, so taking dose is little, and safety is good, and effect rapidly.Though be oral formulations, can reach the effect of ejection preparation.Therefore just progressively become the focus that pharmaceutical manufacturer and research and development field are paid close attention to.This dosage form mainly is to select suitable fast disintegrant, by the existing certain rigidity of its tablet of making, certain sedimentation is arranged again.Can not need the water assisting deglutition when taking, can rapid disintegrate become fine grained in the oral cavity, only several swallowing acts can be finished drug administration process.Its more common solid orally ingestible absorbs fast, bioavailability height, and taking convenience.
The preparation oral cavity disintegration tablet will be considered the problem of following critical aspects: 1, the advantage of oral cavity disintegration tablet just is rapid disintegrate, and it is fast to discharge medicine, reaches rapid-action effect, seeks suitable disintegrants, to guarantee oral cavity disintegration tablet disintegrate rapidly in the oral cavity; 2, seek relatively inexpensive pharmaceutic adjuvant, to reduce production cost; 3, only need the just disintegrate fully of water of minute quantity owing to disintegrating tablet, therefore must consider stability, prolongation shelf life and the shelf-life of humidity environment oral cavity disintegration tablet higher relatively in the process of storage, significant to medical manufacturing enterprise.
Disintegrating agent is commonly used in the oral cavity disintegration tablet adjuvant have low-substituted hydroxypropyl cellulose (L-HPC), cross-linking sodium carboxymethyl cellulose (CCNa), crospolyvinylpyrrolidone (PVPP), crosslinked carboxymethylstach sodium (CCMS-Na) etc. [He Jianchang, etc.New oral solid quick releasing formulation-oral cavity quick disintegrating slice.The pharmacy practice magazine, 2000,18 (3): 151].These adjuvants are all water insoluble, but a common characteristic is all arranged, and have hygroscopicity [pharmaceutical preparation portion of Shanghai Institute of Pharmaceutical Industry, Pharmaceutical National Engineering Research Center exactly.Pharmaceutic adjuvant application technology (second edition), Chinese Medicine science and technology publishing house, 2002,73～75].In the higher environment of humidity, oral cavity disintegration tablet is the moisture absorption especially easily, and cracked trend is arranged.So relatively harsher to environment requirement in production, storage and transportation with the oral cavity disintegration tablet that these adjuvants are made, must adopt special packing, seal cover, desiccant bag etc., all can produce considerable influence to production cost.And above-mentioned disintegrating agent all is synthetic through chemical process, and price is higher, for the more relatively oral cavity disintegration tablet of adjuvant content, can cause production cost to increase, and and then can increase patient's financial burden.Therefore, seek disintegrating agent functional, that price is suitable, make that the disintegration time of oral cavity disintegration tablet is shorter, price is more cheap, stability better becomes one of key problem in technology of exploitation oral cavity disintegration tablet.
Application number is 99802175 patent application bibliographical information, and during as disintegrating agent, the hardness of making oral cavity disintegration tablet is identical with disintegration time at the erythritol that uses separately equivalent or low-substituted hydroxypropyl cellulose (L-HPC).The erythritol sweet taste is pure, after eating nice and cool mouthfeel characteristic is arranged, and also can make correctives and use, and reduces the weight of oral cavity disintegration tablet.Erythritol can not influence normal carbohydrate metabolism, is fit to diabetes patient; And be sweet taste material low in calories, be suitable for obese patients, simultaneously caries prevention is also had positive role.
Chitin is the relatively low natural pharmaceutic adjuvant of a kind of price, and it has another name called chitin, chitin, is a kind of biological polysaccharide polymer material, extensively is present in the carapace in the unicellular lower eukaryote.This material can be degraded by lyase, has excellent biological compatibility, avirulence, chemical property quite stable.
The medicinal part of panax araliaceae plant has the branch of main root, supporting root (practise and claim " rib ") and rhizome (practise and claim " clip ", " reed head ").Main root is main medicinal part, by the Radix Notoginseng total arasaponins that main root is obtained through refining by certain technology, has blood circulation promoting and blood stasis dispelling, a demountable function of promoting blood circulation, and has blood vessel dilating, the effect of anticoagulant.Be used for the treatment of diseases of cardiovascular and cerebrovascular systems, apoplexy sequela etc.
The Radix Notoginseng total arasaponins of obtaining through refining by certain technology with the Radix Notoginseng main root is that the preparation of effective ingredient has XUESHUANTONG ZHUSHEYE (WS
3-B-3829-98).Injection uses inconvenience clinically, and safety is bad, thereby use is very restricted.
In patent retrieval, find no any report that closes the XUESHUANTONG oral cavity disintegration tablet.
Summary of the invention
In the selection course that disintegrating agent uses in oral cavity disintegration tablet, we discover that erythritol and disintegrating agent commonly used at present mix by a certain percentage, form a kind of compound disintegrating agent and have more performance, the oral cavity disintegration tablet made from it compares with the simple oral cavity disintegration tablet that uses erythritol or disintegrating agent commonly used at present to make, the disintegration time of oral cavity disintegration tablet was shortened, and because erythritol has very little hygroscopicity, the stability of the feasible oral cavity disintegration tablet of making significantly improves.In the compound disintegrating agent, erythritol is in the amount ranges of 30%-70%, and along with the increase of content, the disintegration time of oral cavity disintegration tablet shortens, and stability strengthens.
We find that in experiment chitin disintegrating agent effect with commonly used at present aspect the disintegrate effect is suitable, even are better than disintegrating agent commonly used.
We have studied compound disintegrating agent in experiment, select the mixture of use erythritol and chitin, disintegrating agent commonly used, are based on many-sided consideration.When making disintegrating agent with single erythritol, though erythritol has very little hygroscopicity, the tablet stability of making is good, and the swelling degree after the single erythritol suction is less, influences the disintegrating property of oral cavity disintegration tablet, and disintegration time is prolonged.Add a certain amount of disintegrating agent commonly used, utilize rapid expansible character after their moisture absorptions, neither influence the stability of oral cavity disintegration tablet, also kept the characteristic of its rapid disintegrate, reached reasonable effect.
The objective of the invention is in order to overcome the deficiency that above-mentioned prior art exists, provide a kind of taking convenience, rapid-action to indication, reach the peak early, curative effect obviously, the XUESHUANTONG orally disintegrating tablet preparation of preparation stabilization.
The present invention is achieved through the following technical solutions:
One, process recipes
(1) crude drug consists of: Radix Notoginseng total arasaponins fine powder 5 weight portions;
(2) the preparation prescription proportioning is: Radix Notoginseng total arasaponins 5 weight portions, disintegrating agent 2-6 weight portion, filler 8-15 weight portion, correctives 0.1-1 weight portion, lubricant 0.05-1 weight portion;
(3) Radix Notoginseng total arasaponins is mixed with pharmaceutic adjuvant, granulation, drying, granulate, tabletting, check, packing obtain oral cavity disintegration tablet.
Two, the disintegrating agent performance is investigated experiment
Experimental raw: erythritol, chitin, low-substituted hydroxypropyl methylcellulose, carboxymethyl starch sodium, crosslinked carboxymethyl fecula sodium, insoluble crospolyvinylpyrrolidone, buy by market.
Experimental technique:
(1) solubility experiment: the saturated aqueous solution at 37 ℃ of preparation samples, utilize membrane filter to filter, obtain filtrate, the filtrate of predetermined of accurately weighing is utilized the freeze-drying drying, thereby is obtained the content of water, calculate water-soluble on the water content basis that obtains thus again, the results are shown in Table 1.
(2) viscosity experiment: the saturated aqueous solutions at 37 ℃ of different disintegrating agents of preparation, utilize membrane filter to filter, obtain filtrate, utilize viscometer to obtain filtrate 37 ℃ viscosity, the results are shown in Table 1.
(3) measurement of wettability: precision takes by weighing above-mentioned disintegrating agent, dry weighs fully, is put into 1 week under 25 ℃ and 75% the damp condition, takes by weighing weight, and the calculating wettability the results are shown in Table 1.
(4) volume increases percent: the volume of moisture absorption fore-and-aft survey disintegrating agent, calculate the percent of the volume increase of disintegrating agent, and see Table 1.
Table 1 disintegrating agent performance is investigated relatively
| Disintegrating agent | Dissolubility W/V (37 ℃) | Viscosity mpa.s (37 ℃) | Wettability (%) | Volume increases (%) |
| The insoluble crospolyvinylpyrrolidone of erythritol chitin low-substituted hydroxypropyl methylcellulose carboxymethyl starch sodium crosslinked carboxymethyl fecula sodium | 45 - - - - - | 3.5 - - - - - | 0.03 11.29 14.09 21.07 22.18 22.64 | 0.02 16.57 20.36 22.89 28.14 27.62 |
Conclusion: the characteristics of investigating experiment and oral cavity disintegration tablet by above-mentioned performance, we can analyze, erythritol has very big advantage as disintegrating agent in wettability, but because its moisture pick-up properties is very little, volume increase degree is also very little, therefore, volumetric expansion is slow in disintegrating procedue, can not reach the requirement of the rapid disintegrate of oral cavity disintegration tablet, erythritol is again good correctives simultaneously, not only can be used as disintegrating agent but also can be used as correctives if choose suitable weight, can significantly reduce consumption, the operation in the formulation preparation process and the cost of preparation of pharmaceutic adjuvant; Other disintegrating agent hygroscopicity are too big, cause oral cavity disintegration tablet very poor aspect stable; By analyzing, erythritol is carried out mixing of proper proportion with other disintegrating agent, the compound disintegrating agent as oral cavity disintegration tablet has good advantages.
Three, the selection of compound disintegrating agent
Experimental raw: choose crosslinked carboxymethyl fecula sodium and carry out different proportion with erythritol and mix, mixed proportion is respectively erythritol: crosslinked carboxymethyl fecula sodium=1: 9 or 2: 8 or 3: 7 or 4: 6 or 5: 5 or 6: 4 or 7: 3 or 8: 2 or 9: 1, totally 9 groups, be respectively experimental group 1-9, with experimental group 1-9 and same filler (in microcrystalline Cellulose, the nano micro crystal cellulose a kind of) and lubricant (in magnesium stearate, Pulvis Talci, the Stepanol MG a kind of), carry out tabletting; Change above-mentioned disintegrating agent into chitin,, be experimental group 10, carry out tabletting with same filler, mix lubricant with weight; Change above-mentioned disintegrating agent into weight crosslinked carboxymethyl fecula sodium, with same filler, mix lubricant, experimental group 11 carries out tabletting.
Experimental technique:
(1) hardness of mensuration tablet: utilize the tablet hardness tester to measure the hardness of tablet, the results are shown in Table 2.
(2) stability experiment: tablet is put into 12 weeks under 25 ℃ and 75% the damp condition, observes the tablet spoilage, the results are shown in Table 2.
(3) disintegrate experiment: according to " the disintegration of tablet method of testing of stipulating in the Chinese pharmacopoeia utilizes the disintegrate tester to measure, and the results are shown in Table 2.
(4) disintegrate test in the oral cavity, disintegration time, grittiness, taste to three health adults have tested experimental group the results are shown in Table 2.
The selection of table 2 experimental group disintegrating agent
| Experimental group | Hardness | Spoilage | Disintegration time | The Orally disintegrating time | Grittiness | Taste |
| (kg) | (％) | (s) | (s) | |||
| 1 2 3 4 5 6 7 8 9 10 11 | 4.1 3.9 2.1 2.2 2.2 2.1 2.0 1.9 1.8 4.6 4.8 | 22.1 21.6 9.3. 8.6 8.1 8.6 9.3 9.6 10.2 33.9 36.5 | 42.1 43.6 26.3 25.2 26.1 26.9 26.8 35.9 35.6 54.1 55.6 | 51.2 52.9 32.9 28.3 26.7 27.4 27.3 38.6 39.1 62.9 62.8 | Having seldom to have much has a lot | Bad generally carefully good carefully very poor |
Change above-mentioned chitin, crosslinked carboxymethyl fecula sodium into low-substituted hydroxypropyl methylcellulose, crosslinked carboxymethyl fecula sodium, crosslinked insoluble polyvinylpyrrolidone, experimentize, the result of experimental result and table 2 is close.
Experimental result shows, erythritol is mixed with into the mixing disintegrating agent with other disintegrating agent, has good effect, simultaneously because erythritol has sweet taste, so can reduce or replace correctives to use, by experiment erythritol: the suitable ratio of other disintegrating agent be 3-7: 7-3.
Four, preparation disintegration time mensuration
In order to prove absolutely that the employed compound disintegrating agent of XUESHUANTONG oral cavity disintegration tablet of the present invention has disintegrate characteristics rapidly than single disintegrating agent, we have carried out following experiment: disintegrating agent is selected in the design by table 3 for use, make into oral cavity disintegration tablet with effective ingredient at identical pressure lower sheeting, place the beaker of the 10ml that fills 37 ℃ of water of 5ml, stir with 30 rev/mins speed, measure the disintegration of the oral cavity disintegration tablet that contains different disintegrating agents.
Table 3 preparation disintegration time mensuration
| Experimental group | Disintegrating agent | Disintegration (s) | |
| Form | Consumption (g: g) | ||
| 1 2 3 4 5 6 7 8 | Chitin antierythrite: chitin low-substituted hydroxypropyl methylcellulose antierythrite: low-substituted hydroxypropyl methylcellulose sodium carboxymethyl starch antierythrite: sodium carboxymethyl starch crosslinked carboxymethyl fecula sodium antierythrite: crosslinked carboxymethyl fecula sodium | - 3∶7 - 4∶6 - 5∶5 - 6∶4 | 31.4 18.7 29.3 18.2 39.1 16.8 41.7 16.2 |
| 9 10 | Insoluble crospolyvinylpyrrolidone erythritol: insoluble crospolyvinylpyrrolidone | - 7∶3 | 34.6 14.9 |
The result: the oral cavity disintegration tablet that uses compound disintegrating agent is in 14.9-18.7 all disintegrates and by No. 2 sieves in second; The oral cavity disintegration tablet that uses single disintegrating agent is in 29.3-41.7 all disintegrates and by No. 2 sieves in second.Illustrate that compound disintegrating agent of the present invention has disintegrate characteristics rapidly really.
Five, pharmacology embodiment
1. the influence that rat suppository is formed
30 of the rat of body weight 300-400g are divided into three groups at random, both matched group, XUESHUANTONG ZHUSHEYE group, XUESHUANTONG oral cavity disintegration tablet group.Every group 10.With rat anesthesia (pentobarbital sodium 30-40mg/kg, ip), dorsal position is fixed, separate trachea, insert a plastic bushing, and separation right common carotid artery and left external jugular vein, put into a long silk thread of 6 centimetres in the stage casing of polyethylene tube, with heparin-saline solution, be full of polyethylene tube, after an end of polyethylene tube inserts left external jugular vein, inject anticoagulant heparin accurately by polyethylene tube, and then the other end of polyethylene tube inserted right common carotid artery, and open bulldog clamp, blood flow to polyethylene tube from right common carotid artery, return left external jugular vein, open blood flow Herba Clinopodii after 15 minutes takes out silk thread rapidly and weighs, and gross weight deducts silk thread weight and promptly gets thrombus weight.The animal wet weight of thrombus of blank group and other three groups of administration groups is carried out record, calculate, the result is as shown in table 4:
Table 4 Xueshuantong preparation is to thrombotic influence (X)
| Group | Mus is (only) only | Wet weight of thrombus (mg) |
| Blank group XUESHUANTONG ZHUSHEYE group XUESHUANTONG oral cavity disintegration tablet group | 10 10 10 | 1.89 0.98 * 1.02 * |
Annotate: compare with matched group:
*P＜0.01
Conclusion: XUESHUANTONG oral cavity disintegration tablet of the present invention, XUESHUANTONG ZHUSHEYE and blank group more all have utmost point significant difference (P＜0.01); XUESHUANTONG oral cavity disintegration tablet of the present invention and XUESHUANTONG ZHUSHEYE compare, zero difference; Illustrate that XUESHUANTONG oral cavity disintegration tablet of the present invention suppresses thrombotic effect and XUESHUANTONG ZHUSHEYE is suitable.
2. the influence of anoxia in mice endurance is tested
Get 30 of healthy Kunming mouses, body weight 20～24g.Be divided into matched group at random, XUESHUANTONG ZHUSHEYE group, XUESHUANTONG oral cavity disintegration tablet group.Every group 10, male and female half and half, sub-cage rearing.With the conversion of people's conventional therapy dosage is the dosage of mice.The conversion formula is: tested animal is tried out the body surface area ratio of the body surface area ratio/known animal of dosage=known animals administer amount * tested animal.Control group administered physiological saline, 1 time/d, continuous 13d.1h after the last administration, it is the 150ml port grinding bottle that mice is placed volume respectively, in put the 15g sodica calx, its time-to-live of airtight observation.The results are shown in Table 5.
The influence of table 5 pair mice normobaric hypoxia (X ± SD)
| Group | Mus number (only) | Mean survival time (min) |
| Matched group XUESHUANTONG ZHUSHEYE group XUESHUANTONG oral cavity disintegration tablet group | 10 10 10 | 15.37±1.58 23.64±1.47 * 23.55±1.38 * |
Annotate: compare with matched group:
*P＜0.01
XUESHUANTONG oral cavity disintegration tablet of the present invention and XUESHUANTONG ZHUSHEYE all can improve mice normobaric hypoxia endurance, and mean survival time is than matched group significant prolongation (P＜0.01); But XUESHUANTONG oral cavity disintegration tablet of the present invention is compared zero difference with XUESHUANTONG ZHUSHEYE.Illustrate: XUESHUANTONG oral cavity disintegration tablet of the present invention and XUESHUANTONG ZHUSHEYE can both significantly improve mice normobaric hypoxia endurance.
3. to the anoxybiotic protective effect experiment of mouse cardiac muscle
Get 30 of healthy Kunming mouses, body weight 18～22g is divided into 3 groups at random, matched group, XUESHUANTONG ZHUSHEYE group, XUESHUANTONG oral cavity disintegration tablet group.Every group of male and female half and half, sub-cage rearing.With the conversion of people's conventional therapy dosage is the dosage of mice.The conversion formula is: tested animal is tried out the body surface area ratio of the body surface area ratio/known animal of dosage=known animals administer amount * tested animal.Control group administered physiological saline.Medication: 1 time/d, continuous 6d.1h is with urethane 1.2g/kg intraperitoneal injection of anesthesia after the last administration, and back fixation is separated trachea, with the bulldog clamp folder pipe of holding one's breath, observes electrocardio with electrocardiogram equipment, and writes down the little mousetrap with stopwatch and hold one's breath time of Guan Houzhi electrocardio disappearance.The results are shown in Table 6.
The anoxybiotic influence of table 6 pair mouse cardiac muscle (X ± SD)
| Group | Mus number (only) | Mean survival time (min) |
| Matched group XUESHUANTONG ZHUSHEYE group XUESHUANTONG oral cavity disintegration tablet group | 10 10 10 | 5.73±0.79 11.66±0.68 * 11.74±0.59 * |
Annotate: compare with matched group:
*P＜0.01
XUESHUANTONG oral cavity disintegration tablet of the present invention and XUESHUANTONG ZHUSHEYE all can shield to the mouse cardiac muscle anoxia, and mean survival time is than matched group significant prolongation (P＜0.01); But the XUESHUANTONG oral cavity disintegration tablet is compared both zero differences with XUESHUANTONG ZHUSHEYE; Illustrate: XUESHUANTONG oral cavity disintegration tablet of the present invention and XUESHUANTONG ZHUSHEYE all can shield to the mouse cardiac muscle anoxia.
Above pharmacological evaluation explanation, XUESHUANTONG oral cavity disintegration tablet of the present invention is compared with XUESHUANTONG ZHUSHEYE, and identical bioavailability and therapeutic effect are arranged.But XUESHUANTONG oral cavity disintegration tablet patient of the present invention need not any misery when taking, and can happyly accept.More suitable for the patient who takes for a long time.
Six, preparation embodiment
Embodiment 1
(1) crude drug: Radix Notoginseng total arasaponins fine powder 50g;
(2) preparation prescription is:
Radix Notoginseng total arasaponins 50g
Nano micro crystal cellulose 109g
Erythritol 10g
Low-substituted hydroxypropyl methylcellulose 27g
Magnesium stearate 4g
(3) Radix Notoginseng total arasaponins is mixed with pharmaceutic adjuvant, granulation, drying, granulate, tabletting, check, packing obtain 1000 of oral cavity disintegration tablets.
Embodiment 2
(1) crude drug: Radix Notoginseng total arasaponins fine powder 50g;
(2) preparation prescription is:
Radix Notoginseng total arasaponins 50g
Microcrystalline Cellulose 87g
Erythritol 24g
Carboxymethyl starch sodium 35g
Pulvis Talci 3g
(3) Radix Notoginseng total arasaponins is mixed with pharmaceutic adjuvant, granulation, drying, granulate, tabletting, check, packing obtain 1000 of oral cavity disintegration tablets.
Embodiment 3
(1) crude drug: Radix Notoginseng total arasaponins fine powder 50g;
(2) preparation prescription is:
Radix Notoginseng total arasaponins 50g
Nano micro crystal cellulose 101g
Erythritol 13g
Crosslinked carboxymethyl fecula sodium 29g
Stevioside 5g
Stepanol MG 2g
(3) Radix Notoginseng total arasaponins is mixed with pharmaceutic adjuvant, granulation, drying, granulate, tabletting, check, packing obtain 1000 of oral cavity disintegration tablets.
Embodiment 4
(1) crude drug: Radix Notoginseng total arasaponins fine powder 50g;
(2) preparation prescription is:
Radix Notoginseng total arasaponins 50g
Microcrystalline Cellulose 113g
Erythritol 13g
Crospolyvinylpyrrolidone 19g
Stevioside 3g
Magnesium stearate 2g
(3) Radix Notoginseng total arasaponins is mixed with pharmaceutic adjuvant, granulation, drying, granulate, tabletting, check, packing obtain 1000 of oral cavity disintegration tablets.
XUESHUANTONG oral cavity disintegration tablet specification of the present invention is the 50mg/ sheet, a 2-3 sheet, 3 times on the one.
Claims (6)
1. an XUESHUANTONG oral cavity disintegration tablet is made by Radix Notoginseng total arasaponins and pharmaceutic adjuvant, it is characterized in that, the weight portion proportioning of each composition is: Radix Notoginseng total arasaponins 5, disintegrating agent 2-6, filler 8-15, correctives 0.1-1, lubricant 0.01-1; Wherein disintegrating agent is to contain the compound disintegrating agent that weight percentage is 30%～70% erythritol.
2. oral cavity disintegration tablet as claimed in claim 1, described compound disintegrating agent is selected from following combination: erythritol and chitin, erythritol and low-substituted hydroxypropyl methylcellulose, erythritol and carboxymethyl starch sodium, erythritol and crosslinked carboxymethyl fecula sodium, erythritol and insoluble crospolyvinylpyrrolidone.
3. oral cavity disintegration tablet as claimed in claim 1 is characterized in that, filler wherein is a kind of in microcrystalline Cellulose, the nano micro crystal cellulose.
4. oral cavity disintegration tablet as claimed in claim 1 is characterized in that, correctives wherein is a kind of in mannitol or the stevioside.
5. oral cavity disintegration tablet as claimed in claim 1 is characterized in that, lubricant wherein is a kind of in magnesium stearate or Pulvis Talci or the Stepanol MG.
6. the preparation method of the arbitrary described oral cavity disintegration tablet of claim 1-5 is characterized in that, may further comprise the steps:
(1) preparation prescription weight portion proportioning is: Radix Notoginseng total arasaponins 5, disintegrating agent 2-6, filler 8-15, correctives 0.1-1, lubricant 0.01-1;
(2) Radix Notoginseng total arasaponins is mixed with pharmaceutic adjuvant, granulation, drying, granulate, tabletting, check, packing obtain oral cavity disintegration tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100498494A CN1307973C (en) | 2004-06-25 | 2004-06-25 | Orally disintegrating tablet for dredging vascular thrombus and its preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100498494A CN1307973C (en) | 2004-06-25 | 2004-06-25 | Orally disintegrating tablet for dredging vascular thrombus and its preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1593633A CN1593633A (en) | 2005-03-16 |
| CN1307973C true CN1307973C (en) | 2007-04-04 |
Family
ID=34665841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100498494A Active CN1307973C (en) | 2004-06-25 | 2004-06-25 | Orally disintegrating tablet for dredging vascular thrombus and its preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1307973C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100337615C (en) * | 2005-05-19 | 2007-09-19 | 郭鸿旭 | Oral disintegration tablet prepared from general saponin of notoginseng for treating thrombosis, and preparing technique |
| CN100374119C (en) * | 2005-09-21 | 2008-03-12 | 重庆康刻尔制药有限公司 | Pseudo-ginseng saponin oral disintegration tablet and preparing method |
| CN104382971A (en) * | 2014-03-04 | 2015-03-04 | 珠海市红旌发展有限公司 | Composition containing pseudo-ginseng extract and nanocrystalline cellulose and preparation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1257422A (en) * | 1997-05-27 | 2000-06-21 | 武田药品工业株式会社 | Solid pharmaceutical preparation |
| CN1366933A (en) * | 2001-01-22 | 2002-09-04 | 杨孟君 | Nano Qiyeshen'an preparation medicine and preparation method |
-
2004
- 2004-06-25 CN CNB2004100498494A patent/CN1307973C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1257422A (en) * | 1997-05-27 | 2000-06-21 | 武田药品工业株式会社 | Solid pharmaceutical preparation |
| CN1366933A (en) * | 2001-01-22 | 2002-09-04 | 杨孟君 | Nano Qiyeshen'an preparation medicine and preparation method |
Non-Patent Citations (4)
| Title |
|---|
| 冲剂临床疗效概述 云南中医中药杂志，第17卷第3期 1996 * |
| 冲剂临床疗效概述 云南中医中药杂志，第17卷第3期 1996;口腔崩解片的研究 海南医学，第14卷第9期 2003;用于口腔速溶片研究开发进展 中国食品报 2004 * |
| 口腔崩解片的研究 海南医学，第14卷第9期 2003 * |
| 用于口腔速溶片研究开发进展 中国食品报 2004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1593633A (en) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1307973C (en) | Orally disintegrating tablet for dredging vascular thrombus and its preparation process | |
| CN1253156C (en) | Orally disintegrating tablet of | |
| CN1958010A (en) | Composition preparation of Chinese traditional medicine, and preparation method | |
| CN1281206C (en) | Orally disintegrating tablet of 'Xinxuekang | |
| CN1273116C (en) | Orally disintegrating tablet of gingko leaf and its preparation process | |
| CN1290528C (en) | Medicine for treating toothache | |
| CN1272026C (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN1899397A (en) | Heart activating oral disintergration tablet and its preparing method | |
| CN1271995C (en) | Orally disintegrating tablet of 'Xintongning' and its preparation | |
| CN1891266A (en) | Chinese medicine oral disintegrating tablet for treating angina pectoris, and its preparing method | |
| CN1277569C (en) | Orally disintegrating tablet of 'Shengmai' and its preparation | |
| CN103655969B (en) | A kind of Chinese medicine composition and preparation method thereof with adjusting blood pressure, blood glucose function | |
| CN1313103C (en) | Orally disintegrating tablet of bupleurum root and its preparation | |
| CN1293895C (en) | Oral disintegration tablet for laryngopathy and its preparing method | |
| CN1296070C (en) | Cinnamon twig and poria oral disnitegration tablet and its preparing method | |
| CN102813661B (en) | Application for glycyrrhetinic acid derivatives | |
| CN1277550C (en) | Wild chrysanthemum oral disintegration tablet and its preparing method | |
| CN1111412C (en) | Thrombus clearing soft capsule and preparation technology thereof | |
| CN1283231C (en) | Orally disintegrating tablet and its preparation | |
| CN101057965A (en) | Compound traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular disease | |
| CN1267128C (en) | Orally disintegrating tablet of 'Huoxiang Zhengqi' and its preparation process | |
| CN1278722C (en) | Orally disintegrating tablet of 'Baibaodan' and its preparation | |
| CN1278705C (en) | Orally disintegrating tablet of 'Tongxinluo' and its preparation | |
| CN1899328A (en) | Aescine oral disintegrant tablet and its preparing method | |
| CN1278674C (en) | Orally disintegrating tablet of throat clearing medicine and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN TASLY PHARMACEUTICAL CO., LTD. Effective date: 20050422 Owner name: GUANGDONG TIANZHIJIAO LIFE SCIENCE CO., LTD. Free format text: FORMER OWNER: ZHANG QINGLONG |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20050422 Address after: 510610 Guangzhou Tianhe District City Lin Road No. 150, Tianyu Garden Plaza Accord Room 802 Applicant after: Guangzhou Tianzhijiao Life Technology Co., Ltd. Co-applicant after: Tianjin Tianshili Pharmaceutical Co., Ltd. Address before: 100036, 1, building 1, 1801, Lianhua District, Beijing, Haidian District Applicant before: Zhang Qinglong |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 510610 Guangzhou Tianhe District City Lin Road No. 150, Tianyu Garden Plaza Accord Room 802 Co-patentee after: Tasly Pharmaceutical Group Co., Ltd. Patentee after: Guangzhou Tianzhijiao Life Technology Co., Ltd. Address before: 510610 Guangzhou Tianhe District City Lin Road No. 150, Tianyu Garden Plaza Accord Room 802 Co-patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. Patentee before: Guangzhou Tianzhijiao Life Technology Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Guangzhou City, Guangdong province and Tianhe District 510610 Forest Road No. 150, Tianyu Garden Plaza Accord Room 802 Co-patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Patentee after: Guangzhou Tianzhijiao Life Technology Co., Ltd. Address before: Guangzhou City, Guangdong province and Tianhe District 510610 Forest Road No. 150, Tianyu Garden Plaza Accord Room 802 Co-patentee before: Tasly Pharmaceutical Group Co., Ltd. Patentee before: Guangzhou Tianzhijiao Life Technology Co., Ltd. |